All In Biotech

Drug Trial Radar · NCT07308392

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis.

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

119

Actual

Start

Feb 25, 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis

Conditions

  • Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis

Interventions

  • HRS-7249 injection setDrug

    HRS-7249 injection set

  • SHR-1918 injection setDrug

    SHR-1918 injection set

  • HRS-7249 injection placebo setDrug

    HRS-7249 injection placebo set

  • SHR-1918 injection placebo setDrug

    SHR-1918 injection placebo set

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in mean TG from baseline at weeks 44 and 48 of treatmentTime frame: at 44&48 weeks after the start of administration
  2. Proportion of subjects experiencing AP during the double-blind treatment periodTime frame: within 48 weeks after the start of administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.